EVIDENCE MAP OF COSTS STUDIES IN CYSTIC FIBROSIS SINCE 2000

Author(s)

Martin A
Crystallise Ltd., East Tilbury, UK

OBJECTIVES:  To create an evidence map of studies reporting the direct and indirect costs associated with cystic fibrosis, and the geographical settings in which these studies were conducted. METHODS:  We searched the heoro.com database (www.heoro.com) for costs studies in cystic fibrosis published between and costs reported across the range of geographical locations and interventions. We presented the findings as an evidence map. RESULTS:  We found a total of abstracts. Of these, reported direct costs from countries and seven reported indirect costs from five countries. The most common setting was the United States, with Nine studies were reviews of the international literature. Fourteen studies reported costs of healthcare in general. Specific interventions studied included prenatal or neonatal screening (18 abstracts), antibiotics for respiratory infections (usually Pseudomonas, 11 abstracts), rhDNase and lung transplants and associated treatments (4 abstracts each). Twenty five abstracts were economic models and CONCLUSIONS:  As with many diseases, there is a relative lack of published data on indirect costs of cystic fibrosis, and two-thirds of studies reporting cost data were from just four jurisdictions: Australia, Canada, the UK and the USA.

Conference/Value in Health Info

2017-11, ISPOR Europe 2017, Glasgow, Scotland

Value in Health, Vol. 20, No. 9 (October 2017)

Code

PRS25

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Respiratory-Related Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×